Oct 21, 2020- Third-quarter sales growth of 9.6 percent; organic sales growth of 10.6 percent- Sales growth in Medical Devices and Diagnostics improved significantly versus prior quarter- Continues to strengthen portfolio with several recent new product approvals, including FreeStyle Libre 3, Libre Sense Glucose Sport Biosensor and MitraClip G4 heart device- Oct 19, 2020- New research from the University of Illinois, Urbana-Champaign, Abbott, and U.S. Air Force published in the journal Scientific Reports demonstrates that the right nutrition is directly linked to physical and cognitive performance in active duty men and women in the U.S. Air Force- Research subjects from the U.S. Air Force, who consumed a specialized nutrition drink with key nutrients, showed an 11% improvement in working memory, resulting in better information processing, problem-solving and multitasking skills- When nutrition was combined with an exercise regimen, study participants showed statistically significant improvements in 80% of key fitness and cognition metrics measured
-
Oct 15, 2020- Results from Abbott’s XIENCE™ 28 and XIENCE 90 trials demonstrate non-inferiority of shorter courses of dual antiplatelet therapy in reducing the frequency of post-stenting death, heart attacks and severe bleeding compared with 12 months of dual antiplatelet therapy in patients with high bleeding risk- Late-breaking data confirm the consistent effect of XIENCE stent technology, when applied to complex, high bleeding risk patients
- Oct 12, 2020- Data demonstrates highly reliable test results with 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset- Availability of the new IgM blood test on the ARCHITECT® and Alinity™ platforms is part of Abbott's effort to offer tests across the disease progression of COVID-19- Abbott's IgM test will give a more complete picture of where patients are in their recovery
- Oct 7, 2020- Data show ID NOW performance of 95.0% sensitivity and 97.9% specificity within seven days of symptom onset- ID NOW is the most studied COVID-19 test available; interim post-authorization study evaluated 1,003 people- To date, Abbott has shipped more than 12 million ID NOW tests to all 50 states and provided more than 30 million rapid and lab-based COVID-19 tests in the U.S. since March